PROTAC KDM4 degrader-1

PROTAC KDM4 degrader-1 (Compound 11) (50 nM; 24 h) mediates the degradation of KDM4A in KYSE-150 esophageal cancer cells via a proteasome-dependent, Neddylation-dependent, VHL-dependent ubiquitin-proteasome pathway mechanism^[1].
PROTAC KDM4 degrader-1 (12.3-1000 nM; 24 h) upregulates the level of H3K36me3 in KYSE-150 esophageal cancer cells in a dose-dependent manner after 24 hours of treatment, confirming its target-binding activity^[1].
PROTAC KDM4 degrader-1 (0.0001-10 μM; 7 days) potently inhibits the proliferation of KYSE-150 esophageal cancer cells, with an IC₅₀ of 16 nM^[1].
PROTAC KDM4 degrader-1 (12.3-1000 nM; 24 h) induces G0/G1 cell cycle arrest in KYSE-150 esophageal cancer cells and MOLT-4 T lymphoblast cells after 24 h of treatment^[1].
PROTAC KDM4 degrader-1 (12.3-1000 nM; 72 h) induces apoptosis in KYSE-150 esophageal cancer cells and MOLT-4 T lymphoblastoid cells in a dose-dependent manner after 72 h of treatment; at a concentration of 1000 nM, the early apoptosis rate of KYSE-150 cells is 29% and the late apoptosis rate is 48%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.